This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Age: 18-75 years old, female;
No prior systemic anti-tumor treatment (including chemotherapy, radiotherapy, or other investigational treatments);
PD-L1 test result: CPS ≥ 1;
Presence of measurable lesions at baseline according to RECIST 1.1 criteria;
Patients participating in other clinical trials at the same time, unless they are in an observational, non-interventional clinical study or the follow-up period of an interventional study;
Subjects with rare histopathological types of cervical cancer, such as neuroendocrine carcinoma, sarcoma, etc.;
Subjects who have had other malignant tumors within 3 years before enrollment, except for cervical cancer. Subjects with other malignant tumors that have been cured by local treatment are not excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, breast carcinoma in situ, etc.;
A history of allergic reactions, hypersensitivity reactions, or intolerance to antibody-based drugs; a history of significant allergies to drugs, food, or other substances;
Single group
Camrelizumab
Drug200mg, intravenous drip for 0.5h, Q3W
famotinib
Drug10mg, oral administration, QD
2-year disease-free survival rate
The proportion of cancer patients without recurrence, metastasis, or tumor-related death within 2 years after treatment, for evaluating short-term efficacy.
Click on the lead sponsor to view all of their trials.
Jin LI
Lead sponsor
Fudan University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
